Novartis will price its new Mayzent multiple sclerosis drug at $88,000 dollars p...
Logo of Swiss drugmaker Novartis is seen at its branch in Schweizerhalle near Basel, Switzerland, March 29, 2018. REUTERS/Arnd Wiegmann
ZURICH - Novartis will price its new Mayzent multiple sclerosis drug at $88,000 dollars per year, the Swiss company’s head of pharmaceuticals, Paul Hudson, said. Novartis said on Tuesday it had won U.S. Food and Drug Administration approval for Mayzent, as the company seeks to tap a new group of patients in whom the neurological disease has shifted from intermittent attacks to a gradually worsening progression.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novartis gets U.S. approval for new drug to treat multiple sclerosisNovartis AG won U.S. Food and Drug Administration approval on Tuesday for its ne...
Read more »
White House, Pelosi have early talks on drug pricing legislationDemocrats and the Trump administration have made addressing drug costs a priority, but accomplishing anything could be difficult, especially as the administration takes an aggressive stance trying to overturn Obamacare in federal court
Read more »
Here's why drug prices are so difficult to bring downPoliticians want to cut drug prices, but they face a wall of conflicts, including their own.
Read more »
U.S. oil prices rise above $60 per barrel on tightening supplyU.S. crude prices rose to a four-month high above $60 a barrel after government ...
Read more »
Lawsuit: 10-year-old was drugged, sexually assaulted in US custodyA Guatemalan father is suing two nonprofits that house migrant children for the US government, alleging his 10-year-old son was forced to take psychotropic drugs and sexually assaulted while in custody.
Read more »
Home price gains slow to a 6 1/2-year low, Case-Shiller saysA closely-watched index of home price gains rose at the slowest pace in nearly 7 years in January.
Read more »
Home prices in January see smallest gain in nearly 4 years: S&P Case-ShillerPrices are still rising, but the gains continue to shrink, as fewer buyers are able to afford the homes available for sale.
Read more »
Convicted drug lord Joaquin 'El Chapo' Guzman seeks new trialLawyers for Joaquin Guzman, the Mexican crime lord known as El Chapo, on Tuesday...
Read more »